Capital Research Global Investors Increases Stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Capital Research Global Investors increased its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 29.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,911,525 shares of the company’s stock after acquiring an additional 433,484 shares during the quarter. Capital Research Global Investors owned approximately 6.83% of Establishment Labs worth $88,064,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC lifted its position in shares of Establishment Labs by 9,643.3% in the 3rd quarter. Barclays PLC now owns 31,471 shares of the company’s stock worth $1,362,000 after purchasing an additional 31,148 shares during the period. Assenagon Asset Management S.A. bought a new stake in Establishment Labs during the 4th quarter valued at $12,898,000. HighTower Advisors LLC increased its holdings in shares of Establishment Labs by 32.5% in the 3rd quarter. HighTower Advisors LLC now owns 10,311 shares of the company’s stock valued at $446,000 after acquiring an additional 2,529 shares during the period. Raymond James Financial Inc. bought a new position in shares of Establishment Labs in the 4th quarter worth $5,494,000. Finally, Swiss National Bank lifted its stake in shares of Establishment Labs by 2.7% during the 4th quarter. Swiss National Bank now owns 38,500 shares of the company’s stock worth $1,774,000 after purchasing an additional 1,000 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ESTA has been the subject of a number of recent research reports. Stephens reiterated an “overweight” rating and issued a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th. Needham & Company LLC assumed coverage on shares of Establishment Labs in a research report on Monday, April 14th. They set a “hold” rating for the company. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and an average price target of $57.40.

Establishment Labs Stock Up 4.2 %

NASDAQ:ESTA opened at $31.45 on Monday. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. Establishment Labs Holdings Inc. has a twelve month low of $26.56 and a twelve month high of $60.12. The company has a market cap of $907.21 million, a PE ratio of -12.19 and a beta of 0.77. The company’s 50 day moving average is $36.56 and its two-hundred day moving average is $39.67.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.34). The firm had revenue of $44.51 million during the quarter, compared to analyst estimates of $44.45 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. Analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.